TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Aqueous Depth (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K readings (flat, steep, mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Toronto score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of FB procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of dyspnea, cough, and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concerns about friends learning about a history of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concerns about getting insurance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Late rectal toxicity (grade >or=1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: High-grade telangiectasia (T 2-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rwall volume exposed to doses >40 Gy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of exchange transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed to prepare Calot's triangle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean maximum plasma epinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to achieve maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death risk
Endpoint domain: Mortality/survival
Primary endpoint: Cardiovascular hospitalisation risk
Endpoint domain: Mortality/survival
Primary endpoint: mean delta glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hyperglycemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: white spot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: gingival health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: HOMA-IR value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Agreement between Gram stain class and pathogenic bacteria culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stretch tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absenteeism from day care or school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Influenza-related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Shoulder-tip pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesia requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median morphine demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleeping pattern disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to the first demand of PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meperidine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of 20-HETE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe Apnea Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral desaturation (SjvO2 less than 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Hematuria incidence
Endpoint domain: Adverse events/effects
Primary endpoint: CD8+ T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Data completeness for primary outcome
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Symptoms questionnaire completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary stress test completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of high use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days of high use without medical review within 48 h
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: overall cosmetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute risk of vitamin B‐12 deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute risk of low vitamin B‐12 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean homocysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of pain after prostatic biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reversion rate of HPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of pseudo-foveas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory markers (sTNFR1 and sTNFR2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ADHD Rating Scale‐IV scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants meeting criteria for improvement on Clinical Global Impression Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants experiencing adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Serum phosphate control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of hypercalcemia
Endpoint domain: Adverse events/effects
Primary endpoint: Calcium x phosphate product control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of EMAs in fecal supernatants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-tTG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgA AGA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment of fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Impairment of sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Congenital malformations of the genitalia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: surgeons' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patients' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time intervals before the first request for rescue analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: Graded Prognostic Assessment (GPA)
Endpoint domain: Mortality/survival
Primary endpoint: Urinary excretion of bone resorption markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of treatment for lower ureteral calculi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who lost 5% of their body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of clinical deterioration requiring treatment escalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenchymal transection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total duration of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fasting plasma triacylglycerols change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating levels of free and total triiodothyronine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak systolic pressure-rate product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Physical well-being scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cancer recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Yield of intestinal metaplasia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in knowledge of HIV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastric pH above 6.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dapsone maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower anxiety after consultation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Higher knowledge before consultation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Website satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV RNA <LLOQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pressure of arterial carbon dioxide (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial pressure of arterial oxygen (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak inspiratory pressure (Ppeak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: QAS (Quality-Adjusted Survival)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean change in glucagon during hypoglycemic clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean glucagon DeltaAUC(0-60 min) during meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma UA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FI (Fasting Insulin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AA area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ulcer-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: plasma total and free tryptophan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary healing rate of perianal abscesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary healing rate of pilonidal sinuses or abscesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of perianal abscesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of pilonidal sinuses or abscesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of overall HA
Endpoint domain: Mortality/survival
Primary endpoint: Platelet Reactivity (PAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIMI flow grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0‐72 h of ospemifene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ospemifene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of impairing ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in GSRS reflux dimension score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of OM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of OM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of OM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of OM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean medial displacement of the COR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean superior displacement of the COR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥30% reduction in pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median times to perceptible pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of HPV vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albuminuria reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of ocular hyperaemia
Endpoint domain: Adverse events/effects
Primary endpoint: intragastric mean pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: serum gastrin AUC(0‐24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: plasma levels of rabeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-Adjusted Life Years (QALYs)
Endpoint domain: Mortality/survival
Primary endpoint: Health professional consultation costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Functional sensory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latch scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-T haplotype frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in prevalence of comorbid psychiatric disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean fasting serum glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Client ratings of the therapeutic alliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Therapist ratings of the therapeutic alliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motivational readiness to change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative prevented fraction of lesion progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusing capacity for carbon monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LSM Delta in SIB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIBIC+ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cured time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: melanoma-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Em
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SRe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IVRTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MPIt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin temperature increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing depth improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival bleeding improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcaneus BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Receipt of SSA disability benefits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Responder rate at 6 months with joint protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: R-R interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HF (High Frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average drainage times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of intercostal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological improvement scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke-related mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: SAS and SDS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in perineometry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of positive social information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fn14 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of fingers placed through the handle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings per woman induced
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: knowledge of LDKT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: willingness to talk about LDKT
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: endorsement of benefits of LDKT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality during follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Pressure gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New York Heart Association class dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of first variceal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: remission rate at week 12
Endpoint domain: Mortality/survival
Primary endpoint: Prebronchodilator FEV1 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in bronchial hyperresponsiveness (PC20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oral Hygiene Index Simplified (OHI-S) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Index (GI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) change from baseline corneometer readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: serum NO concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cytotoxicity of daunorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma daunorubicin systemic exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in hand and gross motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement of active left-sided UC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchodilator response to salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abortion rate
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of LV ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of indexed LV end-systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes